Rationale: The degradation of proteins by the ubiquitin proteasome system (UPS) is required for the maintenance of cellular homeostasis in the heart. An important regulator of metabolic homeostasis is AMP-activated protein kinase (AMPK). AMPK activation inhibits protein synthesis and activates autophagy, but whether AMPK plays a role in regulating protein breakdown through the UPS in the heart is not known.
T he heart adapts metabolically, functionally, and structurally to changes in its environment. Any stress that reduces the intracellular [ATP]:[AMP] ratio activates the enzyme AMP-activated protein kinase (AMPK), resulting in an increased provision of energy through substrate metabolism and inhibition of energy-consuming processes, 1 including protein synthesis. 2, 3 A role for AMPK in protein degradation in the heart has not been clearly defined, but recent reports have suggested a possible role for AMPK in protein degradation in skeletal muscle. 4, 5 Intracellular protein degradation in cardiomyocytes is controlled by independent but interrelated processes: ubiquitin proteasome system (UPS)-mediated proteolysis and autophagy. Although macroautophagy can degrade whole organelles, 6, 7 individual proteins are degraded through the UPS. 8 Ubiquitin ligases confer specificity to the system by the selective ubiquitination of target proteins, which are then degraded by the proteasome. Two muscle-specific ubiquitin ligases, muscle atrophy F-box protein (MAFbx) or Atrogin-1, and muscle RING finger protein 1 (MuRF1), are consistently increased in models of skeletal muscle atrophy. Furthermore, mice lacking MAFbx/Atrogin-1 or MuRF1 subjected to atrophic stimuli show reduced levels of skeletal muscle atrophy. 9, 10 Both ligases also play a critical role in regulating cardiomyocyte size and heart muscle mass. The overexpression of MAFbx/Atrogin-1 in the heart blunts the development of cardiac hypertrophy in response to both physiological and pathological hypertrophic stimuli in vivo. 11, 12 Conversely, MuRF1-deficient mice display exaggerated cardiac hypertrophy in response to pressure overload, 13 whereas the overexpression of MuRF1 in cardiomyocytes prevents pharmacologically induced hypertrophy. 14 Collectively , these studies suggest that the proteins targeted for degradation by MAFbx/ Atrogin-1 and MuRF1 are determinants of cardiomyocyte size.
Early studies in the heart in vitro and in vivo demonstrated that nutrient deprivation decreases protein synthesis and increases fractional rates of protein degradation. 15, 16 AMPK is activated during nutrient deprivation to provide energy to maintain normal cellular function. 1 Although it has recently been reported that nutrient deprivation induces autophagy in cardiomyocytes through AMPK, 17 a role of AMPK in the cardiac UPS has never been considered. We have previously proposed that metabolic signals may trigger functional and structural remodeling of the stressed heart, 18 and therefore we set out to test the hypothesis that AMPK regulates MAFbx/ Atrogin-1 and MuRF1 in the heart.
Methods
An expanded Methods section is available in the Data Supplement at http://circres.ahajournals.org.
Statistical Analysis
Results are expressed as meanϮSEM. Analysis was performed using 2-tailed, unpaired Student t test or 1-way ANOVA with Tukey post hoc test. A value of PϽ0.05 was considered significant.
Results

Nutrient Deprivation Upregulates Markers of Protein Degradation in Cardiomyocytes
Protein degradation is increased in the heart in response to nutrient deprivation, leading to cardiac atrophy 15, 16 ; however, the mechanism(s) regulating this process are not entirely known. Molecular mechanisms of skeletal muscle wasting have been investigated before in cultured myoblasts deprived of nutrients. 19 Under these conditions, cell size is drastically reduced and molecular markers of atrophy (ie, atrogenes, including ubiquitin ligases MAFbx/Atrogin-1 and MuRF1) are strongly induced. 20 Akin to myoblasts, we found that nutrient deprivation increased the mRNA expression of both MAFbx/Atrogin-1 and MuRF1 in neonatal cardiomyocytes in a time-dependent manner ( Figure 1A) . The same was the case with glucose deprivation (data not shown). After 24 hours of nutrient deprivation, the protein levels of MAFbx/Atrogin-1 and MuRF1 were similarly increased, which correlated with increased AMPK activation ( Figure 1B ). Furthermore, in cardiomyocytes protein degradation was significantly increased during nutrient deprivation ( Figure 1C ). Treatment with either Bortezomib or 3-methyladenine decreased protein degradation in neonatal cardiomyocytes indicating involvement of both the UPS and macroautophagy, respectively. The effect of either inhibitor was incomplete, however, suggesting that both processes regulate protein degradation in the presence and absence of nutrients. Assessment of protein degradation with simultaneous inhibition of the UPS and au-tophagy was not possible as it resulted in cell death. These data indicate that akin to autophagy, 17 the UPS also plays an important role in regulating protein degradation during nutrient deprivation.
AMPK Regulates the Expression of Ubiquitin Ligases In Vitro and In Vivo
We investigated the effect of direct AMPK activation and inhibition on MAFbx/Atrogin-1 and MuRF1 expression in cardiomyocytes. AICAR (5-aminoimidazole-4-carboxamide-1-␤-D-ribofuranoside) is a known pharmacological activator of AMPK and is readily taken up by cardiomyocytes. AICAR treatment increased MAFbx/Atrogin-1 and MuRF1 mRNA expression and protein levels in a dose-dependent manner (Figure 2A and 2B), whereas Compound C, a potent AMPK inhibitor, decreased MAFbx/Atrogin-1 and MuRF1 expression ( Figure 2C ). The phosphorylation status of acetyl-CoA carboxylase, a direct target of AMPK, was monitored as a marker of AMPK activity. Intraperitoneal injection of AICAR in mice is also sufficient to activate AMPK in vivo. 21, 22 Either acute or chronic AMPK activation increased MAFbx/Atrogin-1 and MuRF1 mRNA levels in the heart in vivo ( Figure 2D ). Additionally, 2 known targets of AMPK in skeletal muscle, GLUT4 23 and UCP3, 24 were also increased in the heart with AMPK activation ( Figure 2D ). To establish the specificity of the observed effects, we infected neonatal cardiomyocytes with adenoviral constructs to express either active AMPK (aAMPK) or dominant negative AMPK (dnAMPK). Increasing aAMPK MOI resulted in an upregulation of the mRNA expression and protein levels of MAFbx/ Atrogin-1 and MuRF1, whereas dnAMPK had no significant effect on mRNA expression but slightly decreased protein levels at an MOI of 50 ( Figure 3A through 3C). We next investigated the consequence of AMPK activation and inhibition on proteasome-mediated protein degradation in cardiomyocytes. Analogous to the effects of nutrient deprivation, active AMPK increased protein degradation, which was suppressed by dnAMPK or by the proteasome inhibitor Bortezomib ( Figure 3D ). These data establish that AMPK is directly involved in cardiomyocyte remodeling, both metabolically and structurally, by inhibiting protein synthesis 2,3 and, as shown here, by enhancing protein degradation.
AMPK Activation Regulates the Expression of MuRF1 In Vitro Through Transcription Factor Myocyte Enhancer Factor 2
To gain an understanding of how AMPK regulates the expression of MAFbx/Atrogin-1 and MuRF1, we performed in silico promoter analyses on both genes. These studies revealed a myocyte enhancer factor 2 (MEF2) consensus binding sequence 25, 26 upstream of the MuRF1 transcriptional start site ( Figure 4A ). Several reports have already shown that AICAR activation of AMPK induces MEF2 transcriptional activity in muscle, 27, 28 and we found the same to occur in neonatal cardiomyocytes. To assess MEF2 transcriptional activity in nuclear extracts from neonatal cardiomyocytes, we used the MEF2 TransAM assay. This ELISA-based method detects the binding of proteins within nuclear extracts to immobilized double stranded oligonucleotides containing MEF2 binding sites. 29 We found that pharmacological or genetic activation of AMPK enhanced MEF2 transcriptional activity, whereas inhibition of AMPK decreased this effect ( Figure 4B ). To investigate whether MuRF1 transcription is regulated by AMPK through MEF2, we conducted luciferase reporter gene assays. Vectors encoding the MuRF1 promoter, including the endogenous or mutated MEF2 binding site ( Figure 4C ), were cotransfected in H9c2 cells with a vector encoding ␤-galactosidase as an internal transfection control. Luciferase activity was increased by nutrient deprivation, AICAR treatment, or by transfection with aAMPK and conversely decreased by treatment with Compound C or by transfection with dnAMPK. Furthermore, MuRF1 transcription, regulated by AMPK activation, was abolished when the MEF2 binding site on the MuRF1 promoter was mutated ( Figure 4D ). These results indicate that AMPK promotes MEF2 association with the putative MEF2 binding site in the MuRF1 proximal promoter. To confirm this, we performed chromatin immunoprecipitation assays for endogenous MEF2 on extracts from cardiomyocytes infected with empty adenovirus or adenovirus expressing aAMPK or dnAMPK. In agreement with our other results, we recovered the MuRF1 proximal promoter in MEF2 immunoprecipitates from myocytes expressing aAMPK but not myocytes expressing the dnAMPK or empty virus control. In contrast, distal promoter sequences could not be amplified in MEF2 immunoprecipitates ( Figure 4E ). These data demonstrate that MuRF1 is transcriptionally regulated by AMPK through the transcription factor MEF2.
MEF2 Transcriptional Activity and MuRF1 Transcription Are Regulated by AMPK in the Heart
To validate the role of AMPK in MEF2-regulated cardiac transcription of MuRF1 in vivo, we treated MEF2-lacZ reporter mice 30 with AICAR. Consistent with our findings in isolated cardiomyocytes, cardiac MEF2 transcriptional activity was increased in response to AICAR treatment, as evidenced by increased LacZ staining ( Figure 5A ). We then quantified LacZ staining in cardiac protein extracts with the use of a ␤-galactosidase activity assay. AICAR treatment significantly increased ␤-galactosidase activity to the same extent as isoproterenol, used as a positive control 31 ( Figure  5B ). Increased MEF2 transcriptional activity in response to AMPK activation augmented MuRF1 expression in vivo ( Figure 5C ). Collectively, the results demonstrate that AMPK regulates MEF2-mediated transcription of MuRF1 in vivo.
To determine the consequence of AMPK-regulated MuRF1, we investigated whether AMPK-mediated protein degradation through the UPS requires MuRF1. We isolated adult mouse cardiomyocytes from wild-type (WT) or MuRF1 knockout hearts and measured rates of protein degradation in vitro ( Figure 6 ). Proteasome-mediated protein degradation was not altered in the absence of MuRF1 under normal conditions, as WT and MuRF1 Ϫ/Ϫ cardiomyocytes were equally responsive to Bortezomib treatment. Similar to neonatal cardiomyocytes, nutrient deprivation increased protein degradation in WT adult cardiomyocytes. Under the same conditions, increases in protein degradation were less marked in MuRF1 deficient cardiomyocytes but were still higher than in controls. When active AMPK was expressed, protein degradation was greatly enhanced in WT myocytes, but it was not increased in the absence of MuRF1. When dnAMPK was expressed, protein degradation was decreased in WT and unchanged in MuRF1-deficient myocytes. Collectively, these data show that MuRF1 is required for AMPK-regulated protein degradation in cardiomyocytes.
To investigate the physiological importance of the AMPK-MuRF1 axis in vivo, we subjected WT and MuRF1 Ϫ/Ϫ mice to 3 days of nutrient deprivation (starvation or fasting). As expected, 3 days of fasting significantly decreased body weight in both WT and MuRF1 Ϫ/Ϫ mice; however heart weight was decreased only in WT mice ( Figure 7A ). Interestingly, ejection fraction was decreased in WT mice in response to fasting, but loss of MuRF1 preserved ejection fraction ( Figure 7B ). Fractional shortening was also decreased after fasting in WT but not MuRF1 Ϫ/Ϫ animals (Online Table I ). MuRF1 gene expression was significantly increased in WT fasted mice ( Figure 7C ). We also investigated 2 known protein targets of MuRF1 in the heart after 3 days of fasting. Indeed, the protein levels of both cardiac myosin-binding protein C (cMyBP-C) 32 and cardiac troponin I (TnI) 33 decreased in WT fasted mice ( Figure 7D and 7E) . MyBP-C is also degraded by Atrogin-1, and therefore it is not surprising that protein levels also trended to decrease in hearts from fasted MuRF1 Ϫ/Ϫ mice. TnI levels, on the other hand, were not significantly decreased in fasted MuRF1 Ϫ/Ϫ hearts, suggesting that degradation of cardiac TnI during fasting requires MuRF1. Together, these data suggest that AMPK-regulated MuRF1 in the heart during fasting is detrimental to structure and function by enhancing the degradation of specific MuRF1 targets in the heart. The proposed MuRF1 transcriptional regulation through the AMPK-MEF2 regulatory axis is summarized in Figure 8 .
Discussion
We have presented evidence in support of the hypothesis that AMP-activated protein kinase regulates ubiquitin ligases in the rodent heart. The present work extends the longestablished concept of the "dynamic state of body constituents" 34 to a specific situation when the heart adapts to changes in its metabolic environment. Protein turnover (protein synthesis and degradation through the UPS and autophagy) constitutes a major line of defense for protein quality control of the cardiomyocyte 35 and is a major mechanism of adaptation in the heart. It is therefore of interest to understand how protein degradation is regulated in the cardiomyocyte under various circumstances. We have previously shown that markers of the UPS are unregulated in the heart in several settings of cardiac remodeling, 36, 37 but how the markers themselves are regulated is not clear. It is known already that AMPK plays a role in cellular homeostasis in part by inhibiting the mTOR pathway 2,3 and thus by decreasing protein synthesis, while at the same time AMPK activates autophagy. 17, 38, 39 Although AMPK itself has been found to be regulated by the UPS, 40 whether AMPK regulates protein degradation through the UPS has not been investigated in the heart until now.
The role of AMPK in fuel homeostasis is well described, and studies have predominantly focused on the effects of AMPK activation on energy substrate metabolism. 41 AMPK␣2, the active subunit highly expressed in the heart, 42 is preferentially localized to the nucleus. 43 Hence, it is not surprising that AMPK also transcriptionally regulates metabolic gene expression. Although little is known about AMPKregulated transcription in the heart, earlier reports in liver show that AMPK activation represses transcription by inactivating the transcription factors p300, HNF4-␣, ChREBP, and TORC2. 44 Consequently, the expression of genes involved in lipogenesis and gluconeogenesis is attenuated. AMPK can also activate transcription by enhancing CREB activity, thus increasing the expression of UCP3 and HKII. 24, 45 The activation of PGC1␣ by AMPK leads to increased mitochondrial gene expression and mitochondrial biogenesis. 23 Additionally, the activation of AMPK in muscle increases GLUT4 transcription by increasing both PGC1␣ 23 and MEF2 transcriptional activity, the latter through inactivation of HDAC5. 46 The role of AMPK in transcription is only now coming into focus. Akin to its yeast homologue SNF-1, 47 AMPK phosphorylates histone 2B in mammalian cells, 48, 49 suggesting that AMPK regulates entire transcriptional programs and not only transcription of individual genes. By providing evidence that AMPK regulates the transcription of ubiquitin ligases MAFbx/Atrogin-1 and MuRF1, key regulators of protein degradation in the heart, this study further expands the role of AMPK in both cellular homeostasis and transcriptional regulation in the heart.
Extensive analyses of the MAFbx/Atrogin-1 and MuRF1 promoters have not yet been reported, but independent studies have begun to elucidate the transcriptional regulation of both ligases. The expression of MAFbx/Atrogin-1 and MuRF1 is positively regulated by the transcription factor FoxO3A in the heart and is negatively regulated through Akt, which suppresses FoxO. 50 -52 TNF␣ increases the expression of MAFbx/ Atrogin-1 and MuRF1 in cardiomyocytes 53 and in skeletal muscle, 54 independent of Akt through Foxo4. 55 In C 2 C 12 myotubes 56 and in vivo, 57 MAFbx/Atrogin-1 and MuRF1 expression is increased by glucocorticoid stimulation, and the transcription factor C/EBP1 has been suggested to regulate MAFbx/Atrogin-1 transcription in a glucocorticoid-dependent manner in skeletal muscle. 58 The IK␤/NF-B pathway also regulates the transcription of MuRF1 in cachexia-induced muscle wasting. 59 More recently, myogenin has been found to regulate transcription of both MAFbx/Atrogin-1 and MuRF1 in an HDAC-dependent manner. 60 Our findings now demonstrate that in the heart, AMPK contributes to the complex transcriptional regulation of ubiquitin ligases in the setting of nutrient deprivation and fasting.
The duration of fasting may be important, because we observed that prolonged fasting results in impaired contractile function of the heart (Figure 7 ). Our findings are in agreement with several reports showing that fasting decreased cardiac function in WT mice on the one hand, 61 and that the absence of MuRF1 spared muscle and heart from atrophy on the other hand. 62 MuRF1 targets EEF1G (a component of the elongation factor complex EF-1) for degradation. 63 It also targets key enzymes involved in ATP production (including aldolase a and pyruvate dehydrogenase). 64 These studies suggest that MuRF1 not only regulates protein degradation but also regulates protein synthesis and pathways of energy metabolism. Based on our in vivo findings, we now propose that during starvation, the absence of MuRF1 is cardioprotective through several different mechanisms. First, MuRF1independent mechanisms regulate protein degradation, but protein synthesis is not inhibited by MuRF1. Conversely, in WT hearts of fasted animals, the presence of MuRF1 is reflected in an imbalance of protein turnover (enhanced protein degradation and decreased protein synthesis). 62 Furthermore, the upregulation of MuRF1 during starvation may degrade metabolic enzymes (such as aldolase a and the pyruvate dehydrogenase complex). Others have found that with fasting, intracellular glucose 6-phosphate and fructose 6-phosphate in the heart are increased, and glucose phosphorylation is decreased, most likely by allosteric inhibition of hexokinase. 65 Glycogen deposition and citrate levels are also increased in the heart during fasting; the latter inhibits phosphofructokinase activity and therefore puts a brake on glycolysis. 66, 67 It is tempting to speculate that MuRF1 interacts with phosphofructokinase because in muscle atrophy, MuRF1 is upregulated and phosphofructokinase is downregulated, 9 and both enzymes can localize to the M-line. 68, 69 Therefore, it is possible that upregulation of MuRF1 during starvation leads to the downregulation of metabolic enzymes, decreased ATP production from glycolysis, and decreased cardiac function. Indeed, we observed that rates of glucose oxidation in hearts from MuRF1 Ϫ/Ϫ animals are at least 3-fold higher than in the hearts from WT animals (Baskin K.K. and Taegtmeyer H., unpublished results).
A further point must be addressed. Beginning in 2002, a number of clinical studies have reported beneficial outcomes in diabetic heart failure patients treated with the AMPK activator metformin. 70 -73 Our experimental findings are not inconsistent with the clinical outcomes because in diabetes, in contrast to fasting, the heart is flooded with oxidizable fuel. AMPK-regulated protein degradation may be protective because of enhanced protein quality control. 35 We conclude that AMPK is a transcriptional regulator of ubiquitin ligases in heart muscle. Activation of AMPK results in increased rates of protein degradation and consequently leads to cardiomyocyte remodeling. Whether the remodeling is beneficial or detrimental may be dependent on the immediate cardiometabolic environment. We speculate that the activation of AMPK results in enhanced availability of intracellular amino acids for either ATP production or the synthesis of new proteins as the heart adapts to a new physiological state.
